Business Context and Reporting Period
Company: Psyence Biomedical Ltd.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Unaudited interim consolidated financial statements for the three and six months ended September 30, 2025, compared to the same periods in 2024.
Filing Date: November 20, 2025
Key Financial Metrics
The provided text is a cover page and exhibit index for the Form 6-K filing. It references the existence of unaudited condensed consolidated financial statements (Exhibit 99.1) and Management's Discussion and Analysis (Exhibit 99.2) but does not contain the actual numerical data.
- Revenue: Not provided in the filing text.
- Profit/Loss: Not provided in the filing text.
- Cash Flow: Not provided in the filing text.
- Margins: Not provided in the filing text.
- Debt and Liquidity: Not provided in the filing text.
Material Changes
The filing text does not provide specific financial figures or comparative analysis to identify material changes versus the prior comparable period. The document serves only to announce the submission of the interim statements.
Guidance, Outlook, and Risks
Management Commentary: The filing includes a Management's Discussion and Analysis (MD&A) as Exhibit 99.2, but the content of this analysis is not included in the provided text.
Guidance and Outlook: No forward-looking statements or guidance are present in the cover page text.
Risks and Contingencies: No specific risks or contingencies are detailed in the provided text.
Investor Verification Checklist
- Review Exhibit 99.1 for the actual unaudited condensed consolidated financial statements to verify revenue, net income, and cash position.
- Consult Exhibit 99.2 (MD&A) for management's explanation of financial performance and operational updates.
- Confirm the company's status as a Foreign Private Issuer filing under Form 20-F.
- Verify the signature authority of Jody Aufrichtig as Chief Executive Officer and Director.